Cancer readily adapts to and resists treatment. Resistant cells become the prominent population in a tumor, creating an untreatable cancer. To prevent this outcome, resistanceBio has built a drug discovery pipeline capable of identifying a targeted multi-pronged attack that adapts to the tumor throughout treatment.
resistanceBio doesn’t see resistance mechanisms as cancer's superpower but instead as a definable and susceptible weakness. With our novel ResCu System, we mimic clinically reported cancer resistance mechanisms, generating a proprietary biobank of resistant cancer cell populations. Leveraging multi-omics measurements, we define the cause of resistance and identify novel biomarkers, drug targets, and drug candidates. Screening these drugs against the biobank, resistanceBio generates a new therapy class—Resistance Therapy—that can attack a complex intractable tumor and drive it to a simpler, more susceptible state.
Streamlined Project to understand how cancer responds to a therapy over time
Identify biomarkers of treatment success and resistance
Discover novel multi-targeted therapeutic approaches that overcome treatment resistance
Cancer is dynamic and diverse allowing it to quickly adapt to therapy. Effective strategies require a multi-targeted approach.
Small populations of cancer cells in a tumor affect the larger disease progression.
Multi-targeted cancer therapy that takes into account the current and future state of the tumor steering it towards a susceptible state.
Powered by diverse experience, driven by the same life-saving mission